HRT risks vs. benefits: what the evidence actually says in 2026.

The one-paragraph summary

For most healthy women who start HRT under age 60 or within 10 years of their final menstrual period, the benefits — hot flash relief, bone protection, better sleep, likely cardiovascular protection, and improved quality of life — outweigh the risks. Absolute risks are small: roughly 1 extra breast cancer per 1,000 women per year with long-duration combined HRT, a small increase in clot risk with oral (but not transdermal) estrogen, and a stroke signal that appears mainly when HRT is started late. This is the consensus position of NAMS 2022, the Endocrine Society, ACOG, and the International Menopause Society.

How to read this guide

The public conversation about HRT has been distorted by a single 2002 press conference on the Women's Health Initiative (WHI). Twenty-plus years of re-analysis, follow-up trials, and observational cohorts have substantially revised how clinicians think about HRT. Two ideas do most of the work in modern menopause medicine:

1. The timing hypothesis. Starting HRT within 10 years of menopause (the "window of opportunity") produces a very different risk-benefit picture than starting it 15 or 20 years later. Most of the scary WHI numbers came from women in their late 60s and 70s starting HRT for the first time.
2. Route matters more than molecule for clot and stroke risk. Transdermal estradiol (patch, gel, spray) bypasses the liver and does not measurably raise VTE risk. Oral estrogen roughly doubles baseline VTE risk. Molecule matters most for breast risk — bioidentical progesterone appears more favorable than synthetic progestins.

The benefits of HRT — what the evidence shows

1. Vasomotor symptoms (hot flashes and night sweats)

HRT is the most effective treatment available. NAMS 2022 reports a 75–80% reduction in frequency and severity of hot flashes within 8–12 weeks of starting an adequate dose. No non-hormonal therapy comes close — SSRIs and gabapentin produce about 30–50% reductions; fezolinetant (Veozah) produces about 50–60%.

2. Genitourinary syndrome of menopause (GSM)

Vaginal dryness, painful intercourse, and recurrent UTIs respond dramatically to local (vaginal) estrogen and systemic HRT. Local estrogen has almost no systemic absorption and is considered safe even for many women with a history of breast cancer, with oncology sign-off.

3. Bone health

HRT prevents postmenopausal bone loss and reduces vertebral, hip, and total fractures. WHI showed a 33% reduction in hip fracture with combined HRT. Bone protection continues for as long as HRT is used but wanes within a few years of stopping.

4. Cardiovascular disease and mortality

When HRT is started within 10 years of menopause, observational and re-analyzed WHI data show reduced coronary heart disease and all-cause mortality. The KEEPS and ELITE randomized trials support the timing hypothesis. HRT is not prescribed for cardiovascular prevention, but it is not the CV risk factor it was once thought to be — when started at the right time.

5. Mood, sleep, cognition, and quality of life

Randomized trials show improvements in sleep quality, mood, joint pain, and overall quality of life. HRT is not an antidepressant, but for women whose mood symptoms track their hormonal transition, it is often the most effective intervention.

The risks of HRT — what the evidence shows

1. Breast cancer

Combined estrogen-progestin HRT is associated with a small increase in breast cancer risk that emerges after about 3–5 years of use. In WHI, the excess was about 8 additional cases per 10,000 women per year — roughly one extra case per 1,000 women per year of use. Estrogen-alone HRT (for women without a uterus) did not increase breast cancer risk in WHI and may modestly reduce it. Observational data (E3N cohort) suggest bioidentical micronized progesterone has a more favorable breast profile than synthetic progestins like medroxyprogesterone acetate.

2. Venous thromboembolism (blood clots)

Oral estrogen roughly doubles baseline VTE risk (still a small absolute risk: about 2 extra events per 1,000 women per year in healthy women under 60). Transdermal estradiol does not raise VTE risk above baseline in the E3N cohort or in randomized data. For any woman with elevated clot risk — obesity, prior VTE, thrombophilia, immobilization — transdermal is preferred.

3. Stroke

WHI showed a small increase in ischemic stroke, concentrated in women who started HRT after age 60 or more than 10 years past menopause. Transdermal estradiol at standard doses does not appear to increase stroke risk.

4. Endometrial cancer

Unopposed estrogen (estrogen without a progestogen) in a woman with a uterus increases endometrial cancer risk substantially. Any woman with an intact uterus who takes systemic estrogen must also take a progestogen — this is not optional.

5. Gallbladder disease

Oral estrogen increases the risk of gallstones and cholecystectomy. Transdermal does not.

Absolute risk in perspective

For a healthy 52-year-old woman on combined transdermal estradiol plus micronized progesterone for 5 years, the estimated additional annual risks are approximately:

• Breast cancer: ~1 extra case per 1,000 women per year (after 3–5 years of use)
• VTE: no measurable increase with transdermal
• Stroke: no measurable increase when started in the window of opportunity
• Endometrial cancer: no increase when progesterone dosing is adequate

Compared with everyday risks (obesity, alcohol, sedentary lifestyle), the incremental HRT risk in a well-selected patient is modest. Compared with the alternative — untreated moderate-to-severe vasomotor symptoms, accelerated bone loss, and reduced quality of life — the risk-benefit calculation for most healthy women favors treatment.

Who should not take HRT

Absolute contraindications:

• Current or personal history of breast cancer
• Active or recent venous thromboembolism
• Active liver disease
• Undiagnosed abnormal vaginal bleeding
• Known or suspected pregnancy
• Personal history of estrogen-dependent cancer
• Recent stroke or myocardial infarction

Relative contraindications (prescribed with caution and specialist input): migraine with aura, high cardiovascular risk, active gallbladder disease, high-risk family history of breast cancer.

How Kindr approaches risk-benefit

1. You complete an intake covering medical history, family history, symptoms, and current medications.
2. A board-certified clinician licensed in your state reviews within one business day.
3. Where indicated, the default starting regimen is transdermal 17β-estradiol plus micronized progesterone (Prometrium) for women with a uterus — the regimen with the most favorable modern risk-benefit profile.
4. Symptom check-in at 8–12 weeks; annual review thereafter. Duration is individualized, not capped at 5 years.

Sources

• NAMS 2022 Hormone Therapy Position Statement
• ACOG Practice Bulletin: Management of Menopausal Symptoms
• Endocrine Society 2015 Clinical Practice Guideline: Treatment of Symptoms of the Menopause
• Women's Health Initiative long-term follow-up (JAMA 2017; JAMA 2020)
• KEEPS and ELITE randomized trials (timing hypothesis)
• E3N French cohort — progestogen type and breast risk; transdermal and VTE
• ESHRE/IMS 2016 Global Consensus on Menopausal Hormone Therapy

Frequently asked questions

Related: FDA peptide review July 2026 briefing · Peptide therapy hub · Longevity service

Medically reviewed by Kindr Health Clinical Team · Last reviewed 2026-06-19. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products.